EPZM Insider Trading Activity and SEC Form 4 Filings
EPZM insider trading summary
No open-market insider purchases or sales of Epizyme, Inc. (EPZM) have been reported on SEC Form 4 in the past 12 months.
Latest EPZM insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 11, 2022 | Jeffery Kutok | Chief Scientific Officer | Sell | $2K (2,741 @ $0.90) |
| Feb 7, 2022 | Shefali Agarwal | See Remarks | Sell | $2K (1,058 @ $1.50) |
| Feb 7, 2022 | Joseph Beaulieu | Corporate Controller | Sell | $333 (222 @ $1.50) |
| Feb 2, 2022 | Joseph Beaulieu | Corporate Controller | Sell | $941 (687 @ $1.37) |
| Feb 2, 2022 | Shefali Agarwal | See Remarks | Sell | $4K (2,639 @ $1.37) |
| Feb 2, 2022 | Jeffery Kutok | Chief Scientific Officer | Sell | $4K (2,556 @ $1.37) |
| Jan 31, 2022 | Pablo G. Legorreta | Director | Buy | $34.0M (22,666,667 @ $1.50) |
| Jan 31, 2022 | RPI Finance Trust | 10% Owner | Buy | $34.0M (22,666,667 @ $1.50) |
| Jan 31, 2022 | RP Management, LLC | 10% Owner | Buy | $34.0M (22,666,667 @ $1.50) |
| Jan 26, 2022 | Shefali Agarwal | See Remarks | Sell | $6K (2,922 @ $2.02) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.